Candel Therapeutics, Inc. CADL Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLongTermDebtNoncurrent.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s long-term debt?
- Candel Therapeutics, Inc. (CADL) reported long-term debt of $1.05M in Q1 2026.
- How has Candel Therapeutics, Inc.'s long-term debt changed year-over-year?
- Candel Therapeutics, Inc.'s long-term debt increased by 15.8% year-over-year, from $904K to $1.05M.
- What is the long-term trend for Candel Therapeutics, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s long-term debt has grown at a 15.9% compound annual growth rate (CAGR), from $483K to $1.01M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.